20:07 , Aug 16, 2017 |  BC Week In Review  |  Clinical News

Amylyx begins Phase II of AMX0035 for ALS

Amylyx Pharmaceutical Corp. (Cambridge, Mass.) began the Phase II CENTAUR trial to evaluate twice-daily oral AMX0035 for 24 weeks in 132 patients with amyotrophic lateral sclerosis (ALS). The double-blind, placebo-controlled, U.S. trial will evaluate the...